SCHEMBL368446

SCHEMBL368446

O=C(Cl)c1cc(-c2cccnc2)no1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
CYP2A6 P11509 2/20 0.54
CYP2E1 P05181 1/20 0.54
CYP2B6 P20813 1/20 0.54
NAMPT P43490 1/20 0.51
USP30 Q70CQ3 1/20 0.48
BRAF P15056 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
RAB9A P51151 2/20 0.47
CHRNB2 P17787 1/20 0.45
CHRNA5 P30532 1/20 0.45
CHRNA4 P43681 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.44
KMO O15229 2/20 0.43
CYP1A2 P05177 3/20 0.43
CYP3A4 P08684 3/20 0.43
CYP2D6 P10635 1/20 0.43
TP53 P04637 3/20 0.43
CYP19A1 P11511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516614 0.86 CYP2E1 (0.55) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL370074 0.86 CYP2E1 (0.55) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL23930645 0.84 CYP2A6 (0.54) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL30516607 0.84 CYP2E1 (0.57) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL6872027 0.84 CYP2E1 (0.57) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL3045808 0.83 RAB9A (0.64) CYP2C9CYP2C19USP30SMN1; SMN2RAB9A
SCHEMBL30516592 0.81 CYP19A1 (0.51) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL23930576 0.81 CYP2C9 (0.54) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL2112340 0.81 RAB9A (0.74) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL13363888 0.81 CYP19A1 (0.51) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233951-B2 Heterocyclic compounds as pesticides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-12 US disclosed
US-9233951-B2 Heterocyclic compounds as pesticides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-12 US disclosed
US-9233951-B2 Heterocyclic compounds as pesticides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-12 US disclosed
CN-103140483-B Novel heterocyclic compounds as pesticides BAYER CROPSCIENCE AG 2015-06-24 CN disclosed
CN-104086528-A Novel heterocyclic compounds as pesticides BAYER IP GMBH 2014-10-08 CN disclosed
CN-103140483-A novel heterocyclic compounds as pesticides BAYER CROPSCIENCE AG 2013-06-05 CN disclosed
EP-2593447-A2 NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES Bayer Intellectual Property GmbH (DE) 2013-05-22 EP disclosed
US-20120094837-A1 Novel Heterocyclic Compounds as Pesticides BAYER CROP SCIENCE AG (DE) 2012-04-19 US disclosed
US-20120094837-A1 Novel Heterocyclic Compounds as Pesticides BAYER CROP SCIENCE AG (DE) 2012-04-19 US disclosed
US-20120094837-A1 Novel Heterocyclic Compounds as Pesticides BAYER CROP SCIENCE AG (DE) 2012-04-19 US disclosed
WO-2012007500-A2 NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES BAYER CROPSCIENCE AG (DE) 2012-01-19 WO disclosed
WO-2012007500-A2 NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES BAYER CROPSCIENCE AG (DE) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094837-A1 Novel Heterocyclic Compounds as Pesticides DDT, PTMS, ACHE CYP2C9 256/4885CYP2C19 983/4885CYP2A6 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.